|1.||Kieffer, Brigitte L: 12 articles (08/2014 - 01/2003)|
|2.||Zubieta, Jon-Kar: 11 articles (10/2015 - 06/2002)|
|3.||Traynor, John R: 7 articles (12/2014 - 07/2004)|
|4.||Fichna, Jakub: 7 articles (01/2013 - 08/2004)|
|5.||Janecka, Anna: 7 articles (01/2013 - 08/2004)|
|6.||Loh, Horace H: 7 articles (08/2012 - 02/2003)|
|7.||Stohler, Christian S: 6 articles (03/2015 - 06/2002)|
|8.||Vanderah, Todd W: 6 articles (12/2013 - 06/2002)|
|9.||Bilsky, Edward J: 6 articles (12/2013 - 02/2004)|
|10.||Lötsch, Jörn: 6 articles (12/2009 - 01/2003)|
01/01/2013 - "Here we present the first study involving the computational design, expression and characterization of water-soluble variant of a human GPCR, the human mu opioid receptor (MUR), which is involved in pain and addiction. "
07/18/2012 - "Earlier studies have shown that the single nucleotide polymorphism (SNP) A118G (rs1799971) in the opioid receptor mu 1 (OPRM1) gene may affect pain sensitivity. "
10/01/2009 - "The mu-opioid receptor-selective radiotracer-labeled PET studies show that the placebo effects are accompanied by reduction in activation of opioid neural transmission in pain-sensitive brain regions, including rACC, prefrontal cortex, insula, thalamus, amygdala, nucleus accumbens (NAC) and PAG. "
10/01/2006 - "A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain."
03/01/2005 - "The present study showed that both, ORL1 and mu-opioid receptors were expressed in areas of the spinal cord, concerned with transmission of pain signals. "
07/01/2006 - "The present study investigated whether the loss of spinal mu-opioid receptors following peripheral nerve injury is related to mechanical allodynia. "
06/28/2005 - "The present study demonstrates that pretreatment with Derm-sap, a selective toxin for neurons that contain mu opioid receptor (MOR), specifically decreases MOR and blocks EA anti-hyperalgesia. "
01/01/2015 - "Recent evidence implicates a splice variant of the mu opioid receptor known as MOR-1K in the emergence of opioid-induced hyperalgesia. "
01/01/2014 - "Also, while intrathecal administration of exogenous EM2 attenuated allodynia and central sensitization, the mu-opioid receptor antagonist β-funaltrexamine facilitated these events. "
12/01/2009 - "Four days after PTX injection, thermal hyperalgesia was observed, together with increased coupling of excitatory Gs-protein to mu-opioid receptors in the spinal cord. "
|3.||Neuralgia (Stump Neuralgia)
08/01/2005 - "Our results further support the efficacy of mu-opioid receptor agonists in alleviating signs of neuropathic pain in animal models of peripheral and especially central nerve injury."
11/12/2015 - "Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5)."
04/01/2015 - "The in vivo pharmacology of the sigma 1 receptor (σ1R) is certainly complex; however, σ1R antagonists are of therapeutic interest, because they enhance mu-opioid receptor (MOR)-mediated antinociception and reduce neuropathic pain. "
08/31/2008 - "Peripherally acting mu-opioid receptor agonist attenuates neuropathic pain in rats after L5 spinal nerve injury."
05/13/2008 - "Data suggest that BLF-induced spinal antihyperalgesia could be due to activation of the NO-cGMP-PKG-K+ channel pathway and it is not mediated by mu-opioid receptor in a model of neuropathic pain."
12/01/2015 - "▼Naloxegol (Moventig-AstraZeneca) is a peripherally acting mu-opioid receptor antagonist licensed for the treatment of opioid-induced constipation in adults who have had an inadequate response to laxative treatment.(1) It was launched in the United Kingdom in October 2015. "
08/01/2015 - "Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation."
07/01/2015 - "Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation."
01/01/2014 - "Agonists at the mu opioid receptor (MOPr) continue to be vital in the treatment of many forms of chronic pain, but side-effects limit their clinical utility and range from relatively mild, such as constipation, to major, such as addiction and dependence. "
10/01/2009 - "The constipation-induced reduction in the patient's quality of life was improved using 12 mg methylnaltrexone, a peripheral mu-opioid receptor antagonist, administered subcutaneously twice a week."
06/01/2009 - "Peripherally acting mu-opioid receptor antagonists and postoperative ileus: mechanisms of action and clinical applicability."
08/02/2006 - "Postoperative ileus (POI) is often exacerbated by opioid analgesic use during and following surgery, since mu opioid receptor activation results in a further delay of gastrointestinal (GI) transit. "
04/01/2006 - "Peripherally acting mu-opioid-receptor antagonists and the connection between postoperative ileus and pain management: The anesthesiologist's view and beyond."
03/01/2012 - "Newer medications, such as methlynaltrexone and alvimopan (which are peripherally acting mu opioid receptor antagonists), have become available and have proven beneficial for use with postoperative ileus."
10/01/2007 - "Alvimopan, a peripherally acting mu-opioid receptor antagonist accelerated gastrointestinal (GI) recovery in 5 randomized, double-blind, phase III postoperative ileus trials. "
|1.||Morphine (MS Contin)
|2.||Analgesics (Analgesic Drugs)
|5.||Opioid Analgesics (Opioids)
|6.||Messenger RNA (mRNA)
|8.||Ala(2)-MePhe(4)-Gly(5)- Enkephalin (DAGO)
|1.||Cesarean Section (Caesarean Section)
|4.||Drug Therapy (Chemotherapy)